Limiting the Spread

Tracking Resistance

Improving Stewardship

Developing New Solutions

Only when healthcare providers are able to identify whether an infection is present and if it is drug resistant in minutes rather than days, will we be able to move beyond empiric therapy. On-demand molecular diagnostics have the potential to do just that. Innovative new, on-demand diagnostics will help prevent the inappropriate use and overuse of antimicrobials and preserve our antibiotic weapons now and in the future.

 

If the world is serious about tackling the threat of drug-resistant infections, we need to fully embrace the step-change in technology that rapid point-of-care diagnostics represent.”

- Lord Jim O’Neil Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics - The Review on Antimicrobial Resistance (2015)

 

Cepheid’s groundbreaking and innovative development pipeline aims to stay ahead of drug resistance and provide better stewardship solutions

 

Note:Slide the table to see more data

Available Now

2017-2018*

2019-2020*

  • Group A Strep
  • Xpress Flu/RSV
    (CLIA Waived)
  • Xpress Group A Strep
    (CLIA Waived)
  • Vaginitis/Vaginosis
  • Xpress CT/NG
    (CLIA Waived)
  • Xpress
    Vaginitis/Vaginosis
    (CLIA Waived)
  • GI Panel

* Projected menu; subject to change.

O’Neill, J. Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics - The Review on Antimicrobial Resistance. October, 2015.

© 2020 Cepheid.